GeneQuine Biotherapeutics GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeneQuine Biotherapeutics GmbH
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
- Gene Therapy, Cell Therapy